Fed. Circ.'s Claim Construction Rule At Stake In Teva Case
In taking Teva Pharmaceuticals USA Inc.'s appeal of a ruling invalidating patents covering its multiple sclerosis drug Copaxone, the U.S. Supreme Court could dramatically alter how the Federal Circuit reviews claim...To view the full article, register now.
Already a subscriber? Click here to view full article